Literature DB >> 17205403

Assessment of bone metabolism and mineral density in chronic viral hepatitis.

Necati Yenice1, Mübeccel Gümrah, Ozgür Mehtap, Ahmet Kozan, Sembol Türkmen.   

Abstract

BACKGROUND/AIMS: The aim of the study was to assess bone metabolism and impact of disease on bone mineral density in patients with non-cirrhotic chronic hepatitis B or C.
METHODS: 105 patients with chronic hepatitis B or C receiving antiviral agents and 60 healthy controls were included. Subgroups (n=15) were defined on the basis of age (males) or menopausal status (females). Bone mineral density; serum parathyroid hormone (PTH), calcium (Ca), phosphorus (P), total alkaline phosphatase, and 25-hydroxy vitamin D levels; 24-hour urinary levels of Ca and P; and urinary telopeptide (NTX) were measured. Statistical comparisons were made between patient groups and the matched controls.
RESULTS: Compared to controls, the average serum levels of PTH were lower and 24-hour urinary mean Ca levels and T scores were higher in chronic hepatitis B patients between 20 and 40 years of age. Men with chronic hepatitis B and aged 40 - 65 years had lower mean serum P concentrations. Postmenopausal women with chronic hepatitis B had significantly higher NTX levels. Men with chronic hepatitis C had significantly elevated levels of 24-hour mean urinary P levels. The serum 25 OH vitamin D levels were significantly higher in premenopausal women with chronic hepatitis C. Postmenopausal women with chronic hepatitis C had significantly lower serum P concentrations. Other parameters and T scores did not differ significantly between patient groups and matched controls.
CONCLUSION: Our results suggest that chronic hepatitis B and C infections do not pose a risk for osteoporosis and low bone mineral density.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17205403

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  10 in total

1.  Vitamin D status and viral response to therapy in hepatitis C infected children.

Authors:  Azza A Eltayeb; Madleen Adel A Abdou; Amal M Abdel-aal; Mostafa H Othman
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

2.  Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

Authors:  Germán López-Larramona; Alfredo J Lucendo; Sonia González-Castillo; José M Tenias
Journal:  World J Hepatol       Date:  2011-12-27

Review 3.  Osteodystrophy in chronic liver diseases.

Authors:  Pasquale Mansueto; Antonio Carroccio; Aurelio Seidita; Gaetana Di Fede; Antonio Craxì
Journal:  Intern Emerg Med       Date:  2012-01-13       Impact factor: 3.397

4.  Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.

Authors:  Connie Tien; Jason J Xu; Linda S Chan; Mimi Chang; Carolina Lim; Sue Lee; Brian Huh; Shuntaro Shinada; Ho S Bae; Tse-Ling Fong
Journal:  Dig Dis Sci       Date:  2014-09-20       Impact factor: 3.199

5.  Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys.

Authors:  Myong Ki Baeg; Seung Kew Yoon; Sun-Hye Ko; Kyung-Do Han; Hye Jin Choi; Si Hyun Bae; Jong Young Choi; Myung-Gyu Choi
Journal:  Hepatol Int       Date:  2016-02-05       Impact factor: 6.047

6.  Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study.

Authors:  Arash Miroliaee; Mohsen Nasiri-Toosi; Omid Khalilzadeh; Alireza Esteghamati; Alireza Abdollahi; Mehdi Mazloumi
Journal:  Hepatol Int       Date:  2010-07-25       Impact factor: 6.047

Review 7.  Theoretical basis of a beneficial role for vitamin D in viral hepatitis.

Authors:  Khanh vinh quốc Lương; Lan Thi Hoàng Nguyễn
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

8.  Bone mineral density measurements, bone markers and serum vitamin D concentrations in men with chronic non-cirrhotic untreated hepatitis C.

Authors:  Luciana G S Orsini; Marcelo M Pinheiro; Charlles H M Castro; Antônio E B Silva; Vera L Szejnfeld
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

9.  Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients.

Authors:  Masanori Atsukawa; Akihito Tsubota; Noritomo Shimada; Kai Yoshizawa; Hiroshi Abe; Toru Asano; Yusuke Ohkubo; Masahiro Araki; Tadashi Ikegami; Chisa Kondo; Norio Itokawa; Ai Nakagawa; Taeang Arai; Yoko Matsushita; Katsuhisa Nakatsuka; Tomomi Furihata; Yoshimichi Chuganji; Yasushi Matsuzaki; Yoshio Aizawa; Katsuhiko Iwakiri
Journal:  BMC Infect Dis       Date:  2015-08-19       Impact factor: 3.090

10.  Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients.

Authors:  Roger Bedimo; Minhee Kang; Pablo Tebas; Edgar T Overton; Kimberly Hollabaugh; Grace McComsey; Debika Bhattacharya; Christopher Evans; Todd T Brown; Babafemi Taiwo
Journal:  AIDS Res Hum Retroviruses       Date:  2015-11-24       Impact factor: 2.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.